Event led by J.P. Morgan AM & King Abdullah International Medical Research Center convened to discuss the future of healthcare
Sheffield, UK, October 2 2025 – Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, has been awarded the Grand Prize of $1m in research funding at the 2nd Annual Life Sciences Innovation Summit in Saudi Arabia, convened by J.P. Morgan Asset Management and King Abdullah International Medical Research Center. Selected from a cohort of leading global biotech innovators, the Prize recognises the potential of the company’s lead first-in-class regenerative cell therapy Rincell-1 to restore hearing.
The event brought together innovators, investors and industry leaders to explore the latest advancements and trends shaping the future of healthcare in Saudi Arabia.
Dr Simon Chandler, CEO of Rinri Therapeutics, said, ‘This Grand Prize recognises the importance of advancing innovative and impactful therapeutics such as Rincell-1, our lead regenerative cell therapy for hearing loss, which is on the verge of a Phase I trial. We are delighted to be awarded this collaborative funding to accelerate development of our therapies for patients who urgently need them. Thanks are due to J.P. Morgan Asset Management and King Abdullah International Medical Research Center for organising such an insightful conference.’